Amlodipine aspartic acid impurity
Based on 1 Customer Validation
Amlodipine aspartic acid impurity (Amlodipine aspartate) is the impurity of Amlodipine aspartic acid. Amlodipine aspartic acid is a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine aspartic acid impurity can control blood pressure. Amlodipine aspartic acid impurity corrects gut dysbiosis and enhances taurine and hypotaurine metabolism. Amlodipine aspartic acid impurity can be studied in research for NAFLD and hypertension.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.42%
- CAS. Nr.: 400602-35-9
- Formel: C24H29ClN2O9
- Molecular Weight:524.95
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Calcium Channel Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-week-old male C57BL/6J NAFLD and hypertensive mice[1]
-
Dosage:1.4 and 2.8 mg/kg
-
Administration:Intragastric administration (i.g.) once daily for 8 weeks
-
Result:Decreased plasma ALT and AST levels.
Significantly decreased hepatocellular triglyceride level.
Decreased liver injury and hepatic steatosis and improved impaired plasma triglyceride and cholesterol.
Suppressed fatty acid synthesis and fatty acid uptake.
Induced AMP-activated protein kinase activation and downregulated hepatic protein level of active SREBP1c.
Altered the gut micro-environment in mice.
Stimulated the growth of benign bacteria.
Chemical Information
-
CAS. Nr. 400602-35-9
-
Appearance Solid
-
Molecular Weight 524.95
-
Formel C24H29ClN2O9
-
Color Off-white to light yellow
-
Synonyms
Amlodipine aspartate
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 50 mg/mL (95.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Sheraz MA, et al. Formulations of Amlodipine: A Review. J Pharm (Cairo). 2016;2016:8961621. [Content Brief]
[2]. Li, Y., et al., (2022). Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. British journal of pharmacology, 179(9), 2054–2077. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9049 mL | 9.5247 mL | 19.0494 mL | 47.6236 mL |
| 5 mM | 0.3810 mL | 1.9049 mL | 3.8099 mL | 9.5247 mL | |
| 10 mM | 0.1905 mL | 0.9525 mL | 1.9049 mL | 4.7624 mL | |
| 15 mM | 0.1270 mL | 0.6350 mL | 1.2700 mL | 3.1749 mL | |
| 20 mM | 0.0952 mL | 0.4762 mL | 0.9525 mL | 2.3812 mL | |
| 25 mM | 0.0762 mL | 0.3810 mL | 0.7620 mL | 1.9049 mL | |
| 30 mM | 0.0635 mL | 0.3175 mL | 0.6350 mL | 1.5875 mL | |
| 40 mM | 0.0476 mL | 0.2381 mL | 0.4762 mL | 1.1906 mL | |
| 50 mM | 0.0381 mL | 0.1905 mL | 0.3810 mL | 0.9525 mL | |
| 60 mM | 0.0317 mL | 0.1587 mL | 0.3175 mL | 0.7937 mL | |
| 80 mM | 0.0238 mL | 0.1191 mL | 0.2381 mL | 0.5953 mL |
Amlodipine aspartic acid impurity Related Classifications
HY-128696 Related Classifications
Powered by Bioz